{"id":"sirolimus-mmf-or-mps-or-aza-steroid","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Nephrotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus is an mTOR inhibitor that blocks T-cell and B-cell proliferation by preventing cell cycle progression. MMF (mycophenolate mofetil), MPS (mycophenolate sodium), or AZA (azathioprine) inhibit purine synthesis preferentially in lymphocytes. Corticosteroids provide additional immunosuppression through multiple mechanisms. Together, this triple therapy provides potent immunosuppression for transplant rejection prevention.","oneSentence":"This combination regimen suppresses T-cell proliferation and antibody production through mTOR inhibition (sirolimus) and inosine monophosphate dehydrogenase inhibition (MMF/MPS/AZA), used to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:45.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in solid organ transplantation (kidney, heart, liver)"},{"name":"Chronic rejection prevention in transplant recipients"}]},"trialDetails":[{"nctId":"NCT00452361","phase":"PHASE4","title":"Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Kidney Transplantation","enrollment":31},{"nctId":"NCT01213394","phase":"PHASE3","title":"Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Ramesh Prasad","startDate":"2010-10","conditions":"Kidney Transplantation, Cardiovascular Diseases","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sirolimus+MMF or MPS or AZA+Steroid","genericName":"Sirolimus+MMF or MPS or AZA+Steroid","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen suppresses T-cell proliferation and antibody production through mTOR inhibition (sirolimus) and inosine monophosphate dehydrogenase inhibition (MMF/MPS/AZA), used to prevent organ rejection. Used for Prevention of organ rejection in solid organ transplantation (kidney, heart, liver), Chronic rejection prevention in transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}